CHCWM – Cancer & Hematology Centers of West Michigan

Ph1 INBRX-109 (Inhibrix)

An Open Label, Multicenter, First-in-Human, Dose-Escalation Phase I Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas